Ipamorelin for growth hormone support

What the evidence says

Evidence tier: Strong clinical. Multiple human studies support the dosing protocol; not yet FDA-labeled for this exact indication but close.

• Ipamorelin is a selective GHRP (growth-hormone-releasing peptide) - it triggers a GH pulse from your pituitary without raising cortisol or prolactin (which older GHRPs like GHRP-6 do).
• The 'cleaner-side-effect-profile' half of the standard CJC-1295 stack.
• Phase 1 and 2 work (Raun et al., 1998) confirmed the selective GH-only mechanism.

Protocol notes

100-300mcg subcutaneous before bed, 5 days per week. Almost always stacked with CJC-1295.

Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.

What to skip

• Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
• Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
• Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.

Where to go next

• Full Ipamorelin directory entry - status, sourcing, studies, what to skip
• What are peptides - if you skipped the foundation
• How peptides actually work - mechanism in plain English
• The Tier List - which ones to take seriously
• Subscribe to the dispatch

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.

-> Subscribe free